Email this article Ten-year adjuvant hormone therapy for breast cancer: the pros and cons (a review of literature)
- Authors: Portnoy S.M.1, Shendrikova T.A.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
- Issue: No 3-4 (2013)
- Pages: 50-53
- Section: MAMMOLOGY. TREATMENT
- Published: 22.09.2013
- URL: https://ojrs.abvpress.ru/ojrs/article/view/57
- DOI: https://doi.org/10.17650/1994-4098-2013-0-3-4-50-53
- ID: 57
Cite item
Full Text
Abstract
Tamoxifen is one of the basic drugs of adjuvant hormone therapy in patients with hormone-dependent breast tumors. The purpose of this paper is to analyze the results of randomized trials of long-term adjuvant hormone therapy for breast cancer.
About the authors
S. M. Portnoy
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Russian Federation
T. A. Shendrikova
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
Email: shendrikova.tatyana@gmail.com
Russian Federation
References
Supplementary files
